Publication: Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
Date
Date
Date
Citations
Ho, J. N. H. G., Schmidt, D., Lowinus, T., Ryoo, J., Dopfer, E.-P., Gonzalo Núñez, N., Costa-Pereira, S., Toffalori, C., Punta, M., Fetsch, V., Wertheimer, T., Rittmann, M.-C., Braun, L. M., Follo, M., Briere, C., Vinnakota, J. M., Langenbach, M., Koppers, F., Shoumariyeh, K., … et al. (2022). Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood, 140(10), 1167–1181. https://doi.org/10.1182/blood.2022016082
Abstract
Abstract
Abstract
Patients with acute myeloid leukemia (AML) often achieve remission after allogeneic hematopoietic cell transplantation (allo-HCT) but subsequently die of relapse driven by leukemia cells resistant to elimination by allogeneic T cells based on decreased major histocompatibility complex II (MHC-II) expression and apoptosis resistance. Here we demonstrate that mouse-double-minute-2 (MDM2) inhibition can counteract immune evasion of AML. MDM2 inhibition induced MHC class I and II expression in murine and human AML cells. Using xenografts
Metrics
Views
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Views
Citations
Ho, J. N. H. G., Schmidt, D., Lowinus, T., Ryoo, J., Dopfer, E.-P., Gonzalo Núñez, N., Costa-Pereira, S., Toffalori, C., Punta, M., Fetsch, V., Wertheimer, T., Rittmann, M.-C., Braun, L. M., Follo, M., Briere, C., Vinnakota, J. M., Langenbach, M., Koppers, F., Shoumariyeh, K., … et al. (2022). Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood, 140(10), 1167–1181. https://doi.org/10.1182/blood.2022016082